K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population

Human Mutation

Volumn 29, Issue 5, 2008, Pages 689-694

  Do, Ron ^a   Paré, Guillaume ^a   Montpetit, Alexandre ^a   Hudson, Thomas J ^a,e   Gaudet, Daniel ^b,c   Engert, James C ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CHICOUTIMI HOSPITAL   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Association study; Cholesterol; Coronary artery disease; FDFT1; Squalene synthase

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSINE; SQUALENE SYNTHASE;

ADULT; ARTICLE; CANADA; CHOLESTEROL BLOOD LEVEL; CODON; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAMMAL; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; CASE-CONTROL STUDIES; CHOLESTEROL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; QUEBEC;

MAMMALIA;

EID: 42949100260     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20702     Document Type: Article

References (37)

1. Abecasis GR, Cardon LR, Cookson WO. 2000. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 66:279-292.
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
3. Blumenthal RS. 2000. Statins: effective antiatherosclerotic therapy. Am Heart J 139:577-583.
4. Bonne AC, den Bieman MG, Gillissen GF, van Lith HA, van Zutphen LF. 2002. Chromosomal localization of genes involved in biosynthesis, metabolism or transport of cholesterol in the rat. Cytogenet Genome Res 97:183-186.
5. Burnett JR. 2006. Drug evaluation: TAK-475 - an oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs 7:850-856.
6. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Jr, Ridker PM. 2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827.
7. Crawford DC, Carlson CS, Rieder MJ, Carrington DP, Yi Q, Smith JD, Eberle MA, Kruglyak L, Nickerson DA. 2004. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet 74:610-622.
8. Davidson MH. 2007. Squalene synthase inhibition: a novel target for the management of dyslipidemia. Curr Atheroscler Rep 9:78-80.
9. Engert JC, Lemire M, Faith J, Brisson D, Fujiwara TM, Roslin NM, Brewer CG, Montpetit A, Darmond-Zwaig C, Renaud Y, Doré C, Bailey SD, Verner A, Tremblay G, St-Pierre J, Bétard C, Platko J, Rioux JD, Morgan K, Hudson TJ, Gaudet D. 2008. Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. Eur J Hum Genet 16:105-114.
10. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. 1994. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects. Arterioscler Thromb 14:1553-1560.
11. Gensini GF, Comeglio M, Colella A. 1998. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 19(Suppl A):A53-A61.
12. Gielen S, Schuler G, Hambrecht R. 2001. Exercise training in coronary artery disease and coronary vasomotion. Circulation 103:E1-E6.
13. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Philips K, Anderson N. 1998. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 18:441-449.
14. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr, Bangdiwala S, Tyroler HA. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15.
15. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. 2006. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114:2788-2797.
16. McKenzie TL, Jiang G, Straubhaar JR, Conrad DG, Shechter I. 1992. Molecular cloning, expression, and characterization of the cDNA for the rat hepatic squalene synthase. J Biol Chem 267:21368-21374.
17. Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349:1498-1504.
18. Naoumova RP, Bonney SA, Eichenbaum-Voline S, Patel HN, Jones B, Jones EL, Amey J, Colilla S, Neuwirth CK, Allotey R, Seed M, Betteridge DJ, Galton DJ, Cox NJ, Bell GI, Scott J, Shoulders CC. 2003. Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23:2070-2077.
19. Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y. 2003. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 139:911-918.
20. Okazaki H, Tazoe F, Okazaki S, Isoo N, Tsukamoto K, Sekiya M, Yahagi N, Iizuka Y, Ohashi K, Kitamine T, Tozawa R, Inaba T, Yagyu H, Okazaki M, Shimano H, Shibata N, Arai H, Nagai RZ, Kadowaki T, Osuga J, Ishibashi S. 2006. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res 47:1950-1958.
21. Paré G, Serre D, Brisson D, Anand SS, Montpetit A, Tremblay G, Engert JC, Hudson TJ, Gaudet D. 2007. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am J Hum Genet 80:673-682.
22. Perez A, Kupfer S, Chen Y. 2006. Addition of TAK-475 to atorvastatin provides incremental lipid benefits. Circulation 114(18 Suppl):II-113.
23. Piper E, Price G, Chen Y. 2006. TAK-475, a squalene synthase inhibitor improves lipid profile in hyperlipidemic subjects. Circulation 114(18 Suppl):II-288.
24. Qi L, Shen H, Larson I, Barnard JR, Schaefer EJ, Ordovas JM. 2004. Genetic variation at the hormone sensitive lipase: gender-specific association with plasma lipid and glucose concentrations. Clin Genet 65:93-100.
25. Ramensky V, Bork P, Sunyaev S. 2002. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900.
26. Savolainen MJ, Kesaniemi YA. 1995. Effects of alcohol on lipoproteins in relation to coronary heart disease. Curr Opin Lipidol 6:243-250.
27. Stamellos KD, Shackelford JE, Shechter I, Jiang G, Conrad D, Keller GA, Krisans SK. 1993. Subcellular localization of squalene synthase in rat hepatic cells. Biochemical and immunochemical evidence. J Biol Chem 268:12825-12836.
28. Steiner B, Truninger K, Sanz J, Schaller A, Gallati S. 2004. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles. Hum Mutat 24:120-129.
29. Stengard JH, Kardia SL, Hamon SC, Frikke-Schmidt R, Tybjaerg-Hansen A, Salomaa V, Boerwinkle E, Sing CF. 2006. Contribution of regulatory and structural variations in APOE to predicting dyslipidemia. J Lipid Res 47:318-328.
30. Summers C, Karst F, Charles AD. 1993. Cloning, expression and characterisation of the cDNA encoding human hepatic squalene synthase, and its relationship to phytoene synthase. Gene 136 (1-2Che):185-192.
31. Tansey TR, Shechter I. 2001. Squalene synthase: structure and regulation. Prog Nucleic Acid Res Mol Biol 65:157-195.
32. Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. 2006. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol 535:34-42.
33. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ. 2005. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5:352-358.
34. Tozawa R, Ishibashi S, Osuga J, Yagyu H, Oka T, Chen Z, Ohashi K, Perrey S, Shionoiri F, Yahagi N, Harada K, Gotoda T, Yazaki Y, Yamada N. 1999. Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. J Biol Chem 274:30843-30848.
35. Watkins H, Farrall M. 2006. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7:163-173.
36. Yeo G, Hoon S, Venkatesh B, Butge CB. 2004. Variation in sequence and organization of splicing regulatory elements in vertebrate genes. Proc Natl Acad Sci USA 101:15700-15705.
37. Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Ma Q, Sharma SS, Montgomery DS, Middleton LT, Sundseth SS, Mooser V, Grundy SM, Farrer LA. 2005. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res 46:2202-2213.